Xponance Inc. Has $256,000 Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Xponance Inc. grew its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 8.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 24,415 shares of the company’s stock after purchasing an additional 1,891 shares during the period. Xponance Inc.’s holdings in Elanco Animal Health were worth $256,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Allworth Financial LP lifted its position in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after acquiring an additional 2,090 shares in the last quarter. CoreCap Advisors LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth $29,000. Parallel Advisors LLC raised its position in Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock valued at $41,000 after purchasing an additional 1,852 shares in the last quarter. NBC Securities Inc. purchased a new stake in Elanco Animal Health during the first quarter valued at about $40,000. Finally, Versant Capital Management Inc raised its position in Elanco Animal Health by 65.9% during the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wall Street Zen raised Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective for the company in a report on Thursday. William Blair raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a report on Thursday, June 26th. Stifel Nicolaus lifted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, July 2nd. Finally, Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Elanco Animal Health Trading Down 1.2%

NYSE:ELAN opened at $14.78 on Friday. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $15.78. The firm has a 50 day moving average of $13.82 and a 200 day moving average of $11.79. The company has a quick ratio of 1.46, a current ratio of 2.71 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $7.34 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 2.88 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The business’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the company posted $0.34 earnings per share. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.